TITLE

Stem Cell Research: Dreams Becoming Reality

AUTHOR(S)
Studt, Tim
PUB. DATE
March 2012
SOURCE
Laboratory Equipment;Mar2012 Supplement, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the speed up of stem cell research, particularly adult stem cell and embryonic stem cell (ESC) for its potential to grow and develop cells for any organ or tissue within the body. It states that life science and pharmaceutical companies are shifting their research focus to stem cells. It mentions a study conducted by Mesoblast Ltd. researchers which reveals that injection of adult stem cells into Type 2 diabetes afflicted primates lowered blood sugar levels.
ACCESSION #
71887409

 

Related Articles

  • Bad medicine: type 2 diabetes. Spence, Des // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/6/2010, Vol. 340 Issue 7745, p540 

    The author criticizes the influence of the pharmaceutical industry on the policy and management of type 2 diabetes in Great Britain.

  • DRUG UPDATE.  // RN;Jul2002, Vol. 65 Issue 7, p91 

    Reports developments related to pharmaceuticals in the U.S. as of July 2002. Changes in product labeling for two Type 2 diabetes agents; Reasons for changes in labeling for rofecoxib (Vioxx); Approval of the Integra Dermal Regeneration Template, a bilayer skin replacement system for scars...

  • Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. Yong Zhao; Zhaoshun Jiang; Tingbao Zhao; Mingliang Ye; Chengjin Hu; Huimin Zhou; Zhaohui Yin; Yana Chen; Ye Zhang; Shanfeng Wang; Jie Shen; Thaker, Hatim; Jain, Summit; Yunxiang Li; Yalin Diao; Yingjian Chen; Xiaoming Sun; Fisk, Mary Beth; Heng Li // BMC Medicine;2013, Vol. 11 Issue 1, p1 

    Background: The prevalence of type 2 diabetes (T2D) is increasing worldwide and creating a significant burden on health systems, highlighting the need for the development of innovative therapeutic approaches to overcome immune dysfunction, which is likely a key factor in the development of...

  • Product News.  // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p23 

    Reports product developments in the pharmaceutical industry in the U.S. as of December 2002. Approval on the use of Levaquin from Ortho-McNeil Pharmaceutical Inc. for treatment of hospital-acquired pneumonia; Release of Novartis Pharmaceuticals' Clozaril for schizophrenic patients; Use of...

  • Transmitting clinical recommendations for diabetes care via e-mail. Henault, Robert G.; Eugenio, Kenneth R.; Kelliher, Andrew F.; Alexis, George; Conlin, Paul R. // American Journal of Health-System Pharmacy;11/15/2002, Vol. 59 Issue 22, p2166 

    Highlights the success of a group of clinical pharmacy specialists in the U.S. in monitoring glycemic control in patients with type 2 diabetes through clinical recommendations conducted over electronic mail. Background on the clinical recommendations process; Impact on the patients enrolling in...

  • More Amgen M&A; Buying Alantos In $300M Cash Deal. Boggs, Jennifer // BioWorld Today;6/7/2007, Vol. 18 Issue 110, p1 

    This article reports on the plans of biotechnology company Amgen Inc. to acquire Alantos Pharmaceuticals Inc. The deal is worth $300 million. The acquisition will make Alantos a wholly owned subsidiary of Amgen. The deal will provide Amgen rights to Alantos' DPP-IV inhibitor in Phase IIa for...

  • ConjuChem hits primary end-point in phase II trial for diabetes drug.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p9 

    Reports on the positive results disclosed by ConjuChem from its monotherapy phase II clinical trial, designed to evaluate the company's proprietary compound DAC:GLP-1 for the treatment of type 2 diabetes. Assessment of the compound's effectiveness in reducing glucose levels after three months of...

  • Arvind Remedies to collaborate with Adesh University.  // FRPT- Chemical Snapshot;7/ 6/2014, p21 

    The article reports that Chennai, India-based pharmaceutical firm Arvind Remedies has signed a memorandum of understanding (MoU) with Adesh University to produce drugs from botanical sources using the university's patents as of July 2014. Topics covered include the diseases that will be targeted...

  • New second generation diabetes pill.  // British Journal of Community Nursing;Dec2006, Vol. 11 Issue 12, p542 

    The article features the new second-generation Competact diabetes pill in Great Britain in 2006. The drug combines established oral anti-hyperglycemic agents with confirmed tolerability and efficacy. It is simple to use and is a fixed-dose combination for people with type 2 diabetes who are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics